haematology
Blood cancers

Ibrutinib and venetoclax: an all oral, all novel, chemo-free combo for CLL

The combination of ibrutinib and venetoclax is a viable treatment option for patients with CLL, according to new research presented at ASH 2019.  Professor Constantine Tam, from the Peter MacCallum Cancer Centre in Melbourne, presented the findings of the international multicentre CAPTIVATE study. He told delegates that the combination of ibrutinib and venetoclax had previously ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic